Amlodipine Completed Phase 3 Trials for Hypertension,Essential Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00923091Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension
NCT00220220Amlodipine as add-on to Olmesartan in Hypertension
NCT00220233Olmesartan as an add-on to Amlodipine in Hypertension
NCT00437645Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension
NCT00667719A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension
NCT01001572Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
NCT01113047Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
NCT01237223Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
NCT01556997Perindopril Amlodipine for the Treatment of Hypertension
NCT01663233Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
NCT02152306Fimasartan/Amlodipine Combination Phase III
NCT02738632Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients